caa a22 4500 465789552 CHVBK 20180323112019.0 cr unu---uuuuu 170327e19900801xx s 000 0 eng 10.1007/BF00171847 doi (NATIONALLICENCE)springer-10.1007/BF00171847 Phase II trial of carboplatin and vinblastine in adenocarcinoma of the stomach [Elektronische Daten] [David Ginn, David Kelsen, Mario Eisenberger, Robert Heelan, Gordon Magill] Summary: Twenty-five previously untreated patients with advanced adenocarcinoma of the upper gastrointestinal tract were treated with a combination of carboplatin and vinblastine. Two partial responses (duration three months and six months) were seen among 22 evaluable patients. Myelosuppression was the most common toxicity and was generally mild. The 8% response rate, (95% confidence interval 2 to 24%) observed in this study indicated that carboplatin-vinblastine has only modest activity in adenocarcinoma of the upper gastrointestinal tract. Although less toxic, this regimen appears to be less effective than previously reported cisplatin-containing regimens in adenocarcinoma of the upper GI tract. Kluwer Academic Publishers, 1990 carboplatin gastric cancer phase II nationallicence Ginn David aut Kelsen David Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, 10021, New York, NY, USA aut Eisenberger Mario Cornell University Medical College, New York aut Heelan Robert The Department of Medicine, University of Maryland Cancer Center, Baltimore, USA aut Magill Gordon aut Investigational New Drugs Kluwer Academic Publishers 8/3(1990-08-01), 321-324 0167-6997 8:3<321 1990 8 10637 https://doi.org/10.1007/BF00171847 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF00171847 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Ginn David aut NATIONALLICENCE 700 1- Kelsen David Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, 10021, New York, NY, USA aut NATIONALLICENCE 700 1- Eisenberger Mario Cornell University Medical College, New York aut NATIONALLICENCE 700 1- Heelan Robert The Department of Medicine, University of Maryland Cancer Center, Baltimore, USA aut NATIONALLICENCE 700 1- Magill Gordon aut NATIONALLICENCE 773 0- Investigational New Drugs Kluwer Academic Publishers 8/3(1990-08-01), 321-324 0167-6997 8:3<321 1990 8 10637 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer